The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001##

wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

The present invention provides MDM2 inhibitor compounds of Formula I,

##STR00001##

wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Provided is a fluorescent compound for detecting a biomaterial having the following Chemical Formula 1:

##STR00001##

In Chemical Formula 1 above, R.sub.1 and R.sub.5 are the same as or different from each other, and each independently selected from H, —SO.sub.3.sup.- and SO.sub.3H, R.sub.2 and R.sub.6 are the same as each other or each independently selected from hydrogen or methyl R.sub.4 and R.sub.8 are the same as or different from each other, and each independently selected from H, —SO.sub.3.sup.- and (CH.sub.2)SO.sub.3H, R.sub.3 and R.sub.4 can form alkylene chain with arbituary-substituted 3 carbons combined with the nitrogen atom attached with R.sub.3, R.sub.7 and R.sub.8 can form alkylene chain with arbituary-substituted 3 carbons combined with the nitrogen atom attached with R.sub.7, when R.sub.8 and R.sub.8 do not form alkylene chain, R.sub.6, R.sub.7 and R.sub.8 are hydrogen at the same time and the nitrogen atom attached with R.sub.6 and R.sub.7 at the same time forms double bond with the carbon of mother molecule and has positive charge.

Provided is a fluorescent compound for detecting a biomaterial having the following Chemical Formula 1:

##STR00001##

In Chemical Formula 1 above, R.sub.1 and R.sub.5 are the same as or different from each other, and each independently selected from H, —SO.sub.3.sup.- and SO.sub.3H, R.sub.2 and R.sub.6 are the same as each other or each independently selected from hydrogen or methyl R.sub.4 and R.sub.8 are the same as or different from each other, and each independently selected from H, —SO.sub.3.sup.- and (CH.sub.2)SO.sub.3H, R.sub.3 and R.sub.4 can form alkylene chain with arbituary-substituted 3 carbons combined with the nitrogen atom attached with R.sub.3, R.sub.7 and R.sub.8 can form alkylene chain with arbituary-substituted 3 carbons combined with the nitrogen atom attached with R.sub.7, when R.sub.8 and R.sub.8 do not form alkylene chain, R.sub.6, R.sub.7 and R.sub.8 are hydrogen at the same time and the nitrogen atom attached with R.sub.6 and R.sub.7 at the same time forms double bond with the carbon of mother molecule and has positive charge.

A condensed cyclic compound represented by Formula 1: ##STR00001## wherein, in Formula 1, A.sub.1, D.sub.1, and R.sub.11 to R.sub.14 are the same as described in the specification.

A condensed cyclic compound represented by Formula 1: ##STR00001## wherein, in Formula 1, A.sub.1, D.sub.1, and R.sub.11 to R.sub.14 are the same as described in the specification.

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

##STR00001##

Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5] decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

##STR00001##

Disclosed herein are embodiments of a compound having a Formula I

##STR00001##

or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof.

##STR00002##

Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.

Disclosed herein are embodiments of a compound having a Formula I

##STR00001##

or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof. Also disclosed are derivative compounds made from the compound of Formula I. Certain derivative compounds have a Formula V-2, or a salt, solvate, N-oxide, prodrug, diastereomer or enantiomer thereof.

##STR00002##

Also disclosed are method for making and using the disclosed compounds. Certain disclosed embodiments are useful for treating and/or preventing certain diseases and/or disorders, including proliferation diseases, such as leukemia.